AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$SOPH

Xu Zhenyu sold $163K of SOPH

Xu Zhenyu (Chief Scientific Officer) sold 20,000 shares of SOPHiA GENETICS SA (SOPH) at an average of $8.17 ($7.94–$8.41, $0.16M total) across 3 trades over 2026-08-19 to 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Xu Zhenyu
Published Aug 21, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, implying low immediate market impact.

02

Market read

Provides a fresh, low‑impact insider transaction for SOPH; useful for compliance monitoring but limited trading relevance.

03

What to watch

Potential tax planning or diversification motives unrelated to company performance.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

Chief Scientific Officer Xu Zhenyu sold 20,000 shares for $163K via a 10b5‑1 plan, disclosed in a Form 4 filing.

Expected impact

minor downward bias in the short term

Evidence & confidence

Sale size ($163K) is small versus total holdings (566,887 shares) and follows a pre‑arranged plan, suggesting no urgent negative signal.

Market effects

Sector

Minimal impact on the broader genomics sector; insider sales are routine.

Regional

No discernible regional effect.

Global

Limited to investors tracking SOPHiA GENETICS.

Counterpoint

What could challenge this read

If the insider had insider knowledge, the sale could hint at upcoming challenges.

Key entities

  • Officer
    Xu Zhenyu

    Chief Scientific Officer of SOPHiA GENETICS

  • Company
    SOPHiA GENETICS SA

    Swiss genomics and data analytics firm listed on NASDAQ as SOPH

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SOPH insider trading history →

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min